SanBio Company Limited
Notice on the recognition of other income, other expenses and adjustments to corporate taxes, etc.
Recognized foreign exchange gains of 185 million yen, interest income of 22 million yen, financing expenses of 11 million yen, bond interest of 16 million yen, and adjustments to corporate taxes of 58 million yen. Refer to the consolidated quarterly financial results for the fiscal year ending January 2027.
Key Figures
- Foreign exchange gains: 185 million yen (plus)
- Variation in foreign exchange translation adjustment: △142 million yen
- Interest received: 22 million yen
- Financing costs: 11 million yen
- Bond interest: 16 million yen
- Adjustments to corporate taxes, etc.: 58 million yen
AI要約
Key points of earnings
For the second quarter of the fiscal year ending January 2027, other income is mainly from foreign exchange gains, recognized at 185 million yen. In contrast, the evaluation differences related to foreign currency translations of consolidated subsidiaries showed an offsetting movement of -142 million yen. Interest income from fixed deposits is 22 million yen, financing costs 11 million yen, and bond interest 16 million yen. Adjustments to corporate taxes, etc. are recorded at 58 million yen. These will be disclosed in the financial results (Japanese standards, consolidated).
Outlook and impact
This matter is under the non-operating items and may affect the company's overall consolidated earnings, but it is presented as supplementary information to the consolidated results to be summarized in the financial results. Depending on exchange rate movements and trends in financing costs and bond interest, the impact on the consolidated basis may vary.
SanBio Company Limited
Company overview · Stock price · Financial data · All IR
